JP2008505120A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008505120A5 JP2008505120A5 JP2007519533A JP2007519533A JP2008505120A5 JP 2008505120 A5 JP2008505120 A5 JP 2008505120A5 JP 2007519533 A JP2007519533 A JP 2007519533A JP 2007519533 A JP2007519533 A JP 2007519533A JP 2008505120 A5 JP2008505120 A5 JP 2008505120A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- substituted
- phenyl
- double bonds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052736 halogen Inorganic materials 0.000 claims 70
- 125000000217 alkyl group Chemical group 0.000 claims 63
- 150000002367 halogens Chemical class 0.000 claims 57
- 150000001875 compounds Chemical class 0.000 claims 52
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 46
- 125000001424 substituent group Chemical group 0.000 claims 29
- 125000000623 heterocyclic group Chemical group 0.000 claims 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims 22
- 125000005842 heteroatom Chemical group 0.000 claims 21
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 21
- 229910052757 nitrogen Inorganic materials 0.000 claims 20
- 229910052760 oxygen Inorganic materials 0.000 claims 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims 17
- 229910052717 sulfur Inorganic materials 0.000 claims 17
- 125000005843 halogen group Chemical group 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 125000004432 carbon atom Chemical group C* 0.000 claims 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 9
- -1 —C 1 -C 5 alkyl Inorganic materials 0.000 claims 7
- 125000001624 naphthyl group Chemical group 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 2
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 2
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 claims 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 claims 2
- 125000003884 phenylalkyl group Chemical group 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims 1
- 101150092476 ABCA1 gene Proteins 0.000 claims 1
- 102000018616 Apolipoproteins B Human genes 0.000 claims 1
- 108010027006 Apolipoproteins B Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 claims 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 claims 1
- 229930003779 Vitamin B12 Natural products 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 108091022863 bile acid binding Proteins 0.000 claims 1
- 102000030904 bile acid binding Human genes 0.000 claims 1
- 229920000080 bile acid sequestrant Polymers 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 1
- 235000000639 cyanocobalamin Nutrition 0.000 claims 1
- 239000011666 cyanocobalamin Substances 0.000 claims 1
- 229960002104 cyanocobalamin Drugs 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002530 phenolic antioxidant Substances 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 239000011715 vitamin B12 Substances 0.000 claims 1
- 235000019163 vitamin B12 Nutrition 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58527404P | 2004-07-02 | 2004-07-02 | |
| US60/585,274 | 2004-07-02 | ||
| US64610305P | 2005-01-21 | 2005-01-21 | |
| US60/646,103 | 2005-01-21 | ||
| PCT/US2005/023775 WO2006014413A1 (en) | 2004-07-02 | 2005-07-01 | Cetp inhibitors |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010031195A Division JP4491062B1 (ja) | 2004-07-02 | 2010-02-16 | Ｃｅｔｐ阻害薬 |
| JP2011015653A Division JP5543932B2 (ja) | 2004-07-02 | 2011-01-27 | Ｃｅｔｐ阻害薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008505120A JP2008505120A (ja) | 2008-02-21 |
| JP2008505120A5 true JP2008505120A5 (enExample) | 2010-06-24 |
| JP4695139B2 JP4695139B2 (ja) | 2011-06-08 |
Family
ID=35045145
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007519533A Expired - Fee Related JP4695139B2 (ja) | 2004-07-02 | 2005-07-01 | Ｃｅｔｐ阻害薬 |
| JP2010031195A Expired - Fee Related JP4491062B1 (ja) | 2004-07-02 | 2010-02-16 | Ｃｅｔｐ阻害薬 |
| JP2011015653A Expired - Fee Related JP5543932B2 (ja) | 2004-07-02 | 2011-01-27 | Ｃｅｔｐ阻害薬 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010031195A Expired - Fee Related JP4491062B1 (ja) | 2004-07-02 | 2010-02-16 | Ｃｅｔｐ阻害薬 |
| JP2011015653A Expired - Fee Related JP5543932B2 (ja) | 2004-07-02 | 2011-01-27 | Ｃｅｔｐ阻害薬 |
Country Status (37)
Families Citing this family (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7270971B2 (en) * | 2003-10-16 | 2007-09-18 | Merck & Co., Inc. | Fluorescence assay for measuring the rate of cholesterol ester transfer |
| DOP2005000123A (es) * | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
| AU2006265975B2 (en) * | 2005-07-01 | 2011-12-15 | Merck Sharp & Dohme Corp. | Process for synthesizing a CETP inhibitor |
| ATE516016T1 (de) | 2005-12-05 | 2011-07-15 | Merck Sharp & Dohme | Selbstemulgierende formulierungen von cetp- hemmern |
| AR057218A1 (es) * | 2005-12-15 | 2007-11-21 | Astra Ab | Compuestos de oxazolidinona y su uso como pontenciadores del receptor metabotropico de glutamato |
| US8865707B2 (en) * | 2005-12-30 | 2014-10-21 | Merck Sharp & Dohme Corp. | Cholesteryl ester transfer protein inhibitors |
| JP5040036B2 (ja) | 2005-12-30 | 2012-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃｅｔｐ阻害剤として有用な１，３−オキサゾリジン−２−オン誘導体 |
| US7781426B2 (en) * | 2005-12-30 | 2010-08-24 | Merck Sharp & Dohme Corp. | CETP inhibitors |
| WO2007081569A2 (en) * | 2005-12-30 | 2007-07-19 | Merck & Co., Inc. | Cetp inhibitors |
| CN101378731B (zh) * | 2006-02-09 | 2014-03-05 | 默沙东公司 | Cetp抑制剂的聚合物制剂 |
| US8383660B2 (en) | 2006-03-10 | 2013-02-26 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| US7919506B2 (en) | 2006-03-10 | 2011-04-05 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| WO2007136672A2 (en) * | 2006-05-19 | 2007-11-29 | Merck & Co., Inc. | Synthesis of a biaryl synthetic intermediate |
| WO2008082567A1 (en) * | 2006-12-29 | 2008-07-10 | Merck & Co., Inc. | Process for synthesizing a cetp inhibitor |
| US8168815B2 (en) | 2007-01-26 | 2012-05-01 | Kaneq Pharma Inc. | Fused aromatic PTP-1B inhibitors |
| CA2681628C (en) * | 2007-03-16 | 2016-10-18 | Concert Pharmaceuticals, Inc. | Inhibitors of cholesterol ester transfer protein |
| EP2155187B1 (en) | 2007-05-07 | 2016-05-25 | Merck Sharp & Dohme Corp. | Method of treatment using fused aromatic compounds having anti-diabetic activity |
| ES2569660T3 (es) | 2007-06-08 | 2016-05-12 | Mannkind Corporation | Inhibidores de la IRE-1alfa |
| JP2010530418A (ja) * | 2007-06-20 | 2010-09-09 | メルク・シャープ・エンド・ドーム・コーポレイション | ベンゾオキサゾールアリールアミドから誘導されたｃｅｔｐ阻害剤 |
| CA2689523A1 (en) * | 2007-06-20 | 2008-12-24 | Merck Sharp & Dohme Corp. | Cetp inhibitors derived from benzoxazole arylamides |
| JP2010530416A (ja) * | 2007-06-20 | 2010-09-09 | メルク・シャープ・エンド・ドーム・コーポレイション | ベンゾオキサゾールアリールアミドから誘導されたｃｅｔｐ阻害剤 |
| RU2010103104A (ru) | 2007-07-02 | 2011-08-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные имидазола в качестве антагонистов рецептора ccr2 |
| JP5451611B2 (ja) * | 2007-07-26 | 2014-03-26 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックインヒビター |
| AR069207A1 (es) * | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
| CA2708303A1 (en) | 2007-12-11 | 2009-06-18 | Vitae Pharmaceuticals, Inc. | Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
| TW200934490A (en) * | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
| WO2009094169A1 (en) * | 2008-01-24 | 2009-07-30 | Vitae Pharmaceuticals, Inc. | Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| EP2245002A4 (en) * | 2008-02-01 | 2011-08-17 | Amira Pharmaceuticals Inc | AMINOALKYLBIPHENYL ANTAGONISTS N, N 'DISUBSTITUTED FROM D2 RECEPTORS OF PROSTAGLANDIN |
| US8067445B2 (en) * | 2008-02-01 | 2011-11-29 | Panmira Pharmaceuticals, Llc | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors |
| CA2714532A1 (en) * | 2008-02-11 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
| EP2257536A4 (en) | 2008-02-14 | 2011-03-23 | Amira Pharmaceuticals Inc | CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS |
| US8598160B2 (en) * | 2008-02-15 | 2013-12-03 | Vitae Pharmaceuticals, Inc. | Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| US8497381B2 (en) | 2008-02-25 | 2013-07-30 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
| CA2718264A1 (en) * | 2008-03-18 | 2009-09-24 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
| US8426449B2 (en) | 2008-04-02 | 2013-04-23 | Panmira Pharmaceuticals, Llc | Aminoalkylphenyl antagonists of prostaglandin D2 receptors |
| TW201004945A (en) | 2008-05-01 | 2010-02-01 | Vitae Pharmaceuticals Inc | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| KR20110002492A (ko) | 2008-05-01 | 2011-01-07 | 비타이 파마슈티컬즈, 인코포레이티드 | 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제 |
| EP2291370B1 (en) | 2008-05-01 | 2013-11-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| US8063088B2 (en) * | 2008-06-11 | 2011-11-22 | Hoffmann-La Roche Inc. | Imidazolidine derivatives |
| US8846668B2 (en) | 2008-07-25 | 2014-09-30 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| CA2729993A1 (en) | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
| WO2010011314A1 (en) | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1 |
| GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| DE102008049675A1 (de) | 2008-09-30 | 2010-04-01 | Markus Dr. Heinrich | Verfahren zur Herstellung von 3-Aminobiphenylen |
| WO2010039977A2 (en) | 2008-10-01 | 2010-04-08 | Amira Pharmaceuticals, Inc. | Heteroaryl antagonists of prostaglandin d2 receptors |
| US8354454B2 (en) * | 2008-10-01 | 2013-01-15 | Merck Sharp & Dohme Corp. | Prodrugs of oxazolidinone CETP inhibitors |
| US8524748B2 (en) | 2008-10-08 | 2013-09-03 | Panmira Pharmaceuticals, Llc | Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
| TW201028414A (en) | 2009-01-16 | 2010-08-01 | Merck Sharp & Dohme | Oxadiazole beta carboline derivatives as antidiabetic compounds |
| WO2010085528A1 (en) | 2009-01-23 | 2010-07-29 | Schering Corporation | Bridged and fused antidiabetic compounds |
| EP2389226B1 (en) | 2009-01-23 | 2013-11-20 | Merck Sharp & Dohme Corp. | Bridged and fused heterocyclic antidiabetic compounds |
| JP5679997B2 (ja) | 2009-02-04 | 2015-03-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤 |
| EP2393810A1 (en) | 2009-02-05 | 2011-12-14 | Schering Corporation | Phthalazine-containing antidiabetic compounds |
| UA109255C2 (ru) | 2009-04-30 | 2015-08-10 | Берінгер Інгельхайм Інтернешнл Гмбх | Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1 |
| WO2011011123A1 (en) | 2009-06-11 | 2011-01-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure |
| WO2011002910A1 (en) | 2009-07-01 | 2011-01-06 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| KR20120047273A (ko) * | 2009-08-05 | 2012-05-11 | 판미라 파마슈티칼스, 엘엘씨 | Ｄｐ2 길항제 및 이의 용도 |
| JP2011057661A (ja) | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| EP2496589B1 (en) | 2009-11-05 | 2014-03-05 | Boehringer Ingelheim International GmbH | Novel chiral phosphorus ligands |
| EP2523558A4 (en) | 2010-01-15 | 2013-06-19 | Merck Sharp & Dohme | OXADIAZOL BETA CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| EP2576570A1 (en) | 2010-05-26 | 2013-04-10 | Boehringer Ingelheim International GmbH | 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives |
| EP2397473A1 (en) | 2010-06-14 | 2011-12-21 | LEK Pharmaceuticals d.d. | A stable highly crystalline anacetrapib |
| EP2582698B1 (en) | 2010-06-16 | 2016-09-14 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
| WO2011161128A1 (en) | 2010-06-25 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders |
| JPWO2012046681A1 (ja) | 2010-10-04 | 2014-02-24 | 興和株式会社 | 脂質代謝関連ｍＲＮＡの発現抑制剤 |
| CA2814846A1 (en) * | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | Cyclic amine substituted oxazolidinone cetp inhibitor |
| CA2813671A1 (en) | 2010-11-02 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
| EP2468736A1 (en) * | 2010-12-23 | 2012-06-27 | LEK Pharmaceuticals d.d. | Synthesis of intermediates for preparing anacetrapib and derivates thereof |
| EP2468735A1 (en) * | 2010-12-23 | 2012-06-27 | LEK Pharmaceuticals d.d. | Synthesis of intermediates for preparing anacetrapib and derivates thereof |
| US9052326B2 (en) | 2011-01-26 | 2015-06-09 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Method for assessing a subject's risk of having a cardiovascular disease |
| CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| PH12013501829A1 (en) * | 2011-04-12 | 2015-10-23 | Chong Kun Dang Pharmaceutical Corp | Cycloalkenyl aryl derivatives for cetp inhibitor |
| CN103813789A (zh) * | 2011-07-07 | 2014-05-21 | 持田制药株式会社 | 含有高纯度epa的抗肥胖药 |
| CN103648495A (zh) | 2011-07-08 | 2014-03-19 | 诺华股份有限公司 | 在高甘油三酯对象中治疗动脉粥样硬化的方法 |
| JO3210B1 (ar) | 2011-10-28 | 2018-03-08 | Merck Sharp & Dohme | مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة |
| WO2013066768A1 (en) * | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Process for a cetp inhibitor |
| WO2013064188A1 (en) | 2011-11-03 | 2013-05-10 | Lek Pharmaceuticals D.D. | A stable highly crystalline anacetrapib |
| WO2013080999A1 (ja) | 2011-11-29 | 2013-06-06 | 興和株式会社 | ＮＰＣ１Ｌ１及び／又はＬＩＰＧ ｍＲＮＡの発現抑制剤並びに肥満症の予防及び／又は治療剤 |
| KR101436547B1 (ko) * | 2011-11-30 | 2014-09-02 | 주식회사 대웅제약 | 고지혈증의 예방 또는 치료용 약학 조성물 |
| WO2013091696A1 (en) * | 2011-12-21 | 2013-06-27 | Lek Pharmaceuticals D.D. | Synthesis of intermediates for preparing anacetrapib and derivatives thereof |
| WO2013165854A1 (en) * | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | Cyclic amine substituted heterocyclic cetp inhibitors |
| MX347400B (es) | 2012-06-29 | 2017-04-18 | Univ Nac Autónoma De México | Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso. |
| CN103958484B (zh) * | 2012-07-19 | 2015-11-25 | 上海恒瑞医药有限公司 | 噁唑烷酮类衍生物、其制备方法及其在医药上的应用 |
| EP2888006B1 (en) | 2012-08-22 | 2019-04-24 | Merck Sharp & Dohme Corp. | Novel azabenzimidazole tetrahydropyran derivatives useful as ampk activators |
| EP2934518B1 (en) | 2012-12-19 | 2020-02-19 | Merck Sharp & Dohme Corp. | Spirocyclic cetp inhibitors |
| WO2014099834A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Therapeutic thiazolidinone compounds |
| WO2014111953A1 (en) * | 2013-01-17 | 2014-07-24 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Process for preparation of anacetrapib and intermediates thereof |
| AU2014213125B2 (en) * | 2013-01-31 | 2016-06-02 | Chong Kun Dang Pharmaceutical Corp. | Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as CETP inhibitors |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| EP3027619B1 (en) | 2013-07-30 | 2019-01-02 | Merck Sharp & Dohme Corp. | Bicyclic ureas and thiadiazolidine-1,1-dioxides as cetp inhibitors |
| US9688630B2 (en) | 2013-10-10 | 2017-06-27 | Merck Sharp & Dohme Corp. | 3,3′-disubstituted indolines as inhibitors of cholesterol ester transfer protein |
| US9663534B2 (en) | 2013-12-17 | 2017-05-30 | Merck Sharp & Dohme Corp. | Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein |
| CN104955816B (zh) * | 2014-01-14 | 2016-08-31 | 杭州普晒医药科技有限公司 | 一种安塞曲匹的晶型及其制备方法、其药物组合物和用途 |
| CN103923030B (zh) * | 2014-03-27 | 2015-07-22 | 汕头经济特区鮀滨制药厂 | 一种安塞曲匹的关键中间体的合成方法 |
| CN103923031A (zh) * | 2014-04-01 | 2014-07-16 | 汕头经济特区鮀滨制药厂 | 一种安塞曲匹的中间体的合成方法 |
| EP3174537B1 (en) | 2014-07-29 | 2021-06-23 | Merck Sharp & Dohme Corp. | Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein |
| WO2016016157A1 (en) | 2014-07-30 | 2016-02-04 | F. Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
| CN104230835B (zh) * | 2014-09-01 | 2017-01-25 | 福建师范大学 | 一种合成n‑苯乙烯基恶唑烷‑2‑酮衍生物的方法 |
| WO2016067194A1 (en) * | 2014-10-27 | 2016-05-06 | Sun Pharmaceutical Industries Limited | Process for the preparation of anacetrapib and an intermediate thereof |
| CN106032362B (zh) * | 2015-03-10 | 2018-06-19 | 湖南千金湘江药业股份有限公司 | 安塞曲匹的制备方法 |
| MX2018015872A (es) | 2016-06-29 | 2019-04-22 | Orion Corp | Derivados de benzodioxano y su uso farmaceutico. |
| WO2018016743A1 (ko) * | 2016-07-19 | 2018-01-25 | 재단법인 대구경북첨단의료산업진흥재단 | Cetp 억제제로서의 옥사졸리딘온 유도체 화합물 |
| US10851059B2 (en) * | 2016-08-17 | 2020-12-01 | Novartis Ag | Processes and intermediates for NEP inhibitor synthesis |
| CN106496154A (zh) * | 2016-10-18 | 2017-03-15 | 湖南德魅信息技术有限公司 | 安塞曲匹的制备方法 |
| CN106496211A (zh) * | 2016-10-18 | 2017-03-15 | 湖南德魅信息技术有限公司 | 二氟甲基取代的噁唑烷酮化合物及其用途 |
| CN106749075A (zh) * | 2016-11-24 | 2017-05-31 | 山东新华制药股份有限公司 | 阿那曲波的恶唑烷酮中间体的晶型及其制备方法 |
| US20190070178A1 (en) | 2017-08-29 | 2019-03-07 | Dalcor Pharma Uk Ltd., Stockport Zug Branch | Methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events |
| JOP20180092A1 (ar) | 2017-10-13 | 2019-04-13 | Gilead Sciences Inc | مثبطات hiv بروتياز |
| JP2021534236A (ja) | 2018-08-09 | 2021-12-09 | ダルコア ファーマ ユーケー リミテッド，レザーヘッド，ツーク ブランチ | 新規発症２型糖尿病の発生遅延並びに２型糖尿病の進行緩徐化及び治療の方法 |
| SG11202107468YA (en) | 2019-03-07 | 2021-08-30 | Dalcor Pharma Uk Ltd Leatherhead | Methods for treating or preventing heart failure and reducing risk of heart failure |
| TW202104210A (zh) | 2019-04-17 | 2021-02-01 | 美商基利科學股份有限公司 | Hiv蛋白酶抑制劑 |
| JP7675061B2 (ja) | 2019-07-19 | 2025-05-12 | バイオシント アクチェンゲゼルシャフト | ニコチンアミドリボフラノシド塩の製造方法、ニコチンアミドリボフラノシド塩自体、およびその使用 |
| WO2021226208A2 (en) | 2020-05-05 | 2021-11-11 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| KR102698413B1 (ko) | 2020-05-05 | 2024-08-26 | 뉴베일런트, 아이엔씨. | 헤테로방향족 거대환식 에터 화학치료제 |
| WO2022075645A1 (ko) * | 2020-10-08 | 2022-04-14 | 재단법인 대구경북첨단의료산업진흥재단 | Pcsk9 억제제로서 아미노알콜 유도체 및 이를 함유하는 고콜레스테롤 혈증의 예방 또는 치료용 약학적 조성물 |
| WO2023278698A1 (en) * | 2021-06-30 | 2023-01-05 | Apellis Pharmaceuticals, Inc. | Complement inhibition |
| TW202320768A (zh) | 2021-10-01 | 2023-06-01 | 美商努法倫特公司 | 雜芳族大環醚化合物之固體形式、醫藥組成物及製備 |
| WO2025093129A1 (en) | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Treatment and prevention of age-related macular degeneration using a cetp inhibitor |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179442A (en) | 1975-08-29 | 1979-12-18 | York Hartleben | 4-(Alpha-hydroxy-isopropyl)-5-phenyl-oxazolidin-2-one |
| DE2655369A1 (de) * | 1976-12-03 | 1978-06-08 | Schering Ag | 5-(subst. phenyl)-oxazolidinone und deren schwefelanaloga sowie verfahren zu deren herstellung |
| US4851423A (en) | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
| HU203330B (en) | 1987-06-10 | 1991-07-29 | Pfizer | Process for producing oxazolidin-2-one derivatives and hypoglychemic pharmaceutical compositions containing them |
| HU220601B1 (hu) * | 1992-04-30 | 2002-03-28 | Taiho Pharmaceutical Co. Ltd. | Fenoxi-alkil-oxazolidin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| US5482971A (en) * | 1993-10-01 | 1996-01-09 | American Cyanamid Company | Beta3 -adrenergic agents and their use in pharmaceutical compositions |
| EP0675114A1 (en) | 1993-10-15 | 1995-10-04 | Shionogi & Co., Ltd. | Oxazolinone derivative having intracellular phospholipase a 2? inhibitor activity |
| DE69532238T2 (de) * | 1994-04-21 | 2004-10-21 | Schering Ag | Pde iv-inhibitoren zur behandlung der multiplen sklerose |
| FR2729954B1 (fr) * | 1995-01-30 | 1997-08-01 | Sanofi Sa | Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| HUP9702408A3 (en) * | 1995-02-10 | 2000-08-28 | Schering Ag | Use of 5-phenyloxazolidin-2-one derivatives for the preparation of pharmaceutical compositions treating diseases requiring tumour necrosis factor (tnf) inhibition |
| KR19990014856A (ko) | 1995-05-17 | 1999-02-25 | 미디암 디, 메코너헤이 | 살진균성 시클릭 아미드 |
| US5612363A (en) | 1995-06-02 | 1997-03-18 | Berlex Laboratories, Inc. | N,N-di(aryl) cyclic urea derivatives as anti-coagulants |
| PL324291A1 (en) | 1995-06-20 | 1998-05-11 | Du Pont | Anthropodicidal and fungicidal cyclic amides |
| US5846990A (en) | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
| US6310095B1 (en) * | 1995-11-06 | 2001-10-30 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| DE19647380A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
| WO1998023155A1 (en) | 1996-11-26 | 1998-06-04 | E.I. Du Pont De Nemours And Company | Arthropodicidal and fungicidal cyclic amides |
| DE19704243A1 (de) * | 1997-02-05 | 1998-08-06 | Bayer Ag | Neue 2-Amino-substituierte Pyridine |
| PT966447E (pt) * | 1997-03-03 | 2003-07-31 | Boehringer Ingelheim Pharma | Moleculas pequenas uteis no tratamento de doencas inflamatorias |
| EP0986384B1 (en) | 1997-05-07 | 2012-02-22 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
| DE19741400A1 (de) * | 1997-09-19 | 1999-03-25 | Bayer Ag | Benzyl-biphenyle |
| CA2318969A1 (en) | 1998-01-23 | 1999-07-29 | Mikhail F. Gordeev | Oxazolidinone combinatorial libraries, compositions and methods of preparation |
| IT1300055B1 (it) | 1998-04-17 | 2000-04-05 | Boehringer Ingelheim Italia | Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| CZ2002961A3 (cs) | 1999-09-17 | 2002-08-14 | Millennium Pharmaceuticals, Inc. | Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa |
| HN2000000203A (es) * | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
| US6462063B1 (en) | 2000-02-04 | 2002-10-08 | Fibrogen, Inc. | C-proteinase inhibitors |
| JPWO2001072723A1 (ja) | 2000-03-28 | 2004-01-08 | 日本曹達株式会社 | オキサ（チア）ゾリジン誘導体および抗炎症薬 |
| IL156550A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
| AU2002329393B2 (en) | 2001-09-11 | 2008-06-12 | Astrazeneca Ab | Oxazolidinone and/or isoxazoline as antibacterial agents |
| WO2003032981A1 (en) * | 2001-10-16 | 2003-04-24 | Memory Pharmaceuticals Corporation | 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes |
| US7091196B2 (en) | 2002-09-26 | 2006-08-15 | Rib-X Pharmaceuticals, Inc. | Bifunctional heterocyclic compounds and methods of making and using same |
| KR20080008440A (ko) | 2003-03-17 | 2008-01-23 | 니뽄 다바코 산교 가부시키가이샤 | Ｃｅｔｐ 억제제의 약제학적 조성물 |
| UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| DOP2005000123A (es) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
| CN101180288A (zh) | 2005-03-31 | 2008-05-14 | 科学与工业研究会 | 与抗感染药物联用的芳香族取代的戊二烯酸酰胺 |
| JP5040036B2 (ja) * | 2005-12-30 | 2012-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃｅｔｐ阻害剤として有用な１，３−オキサゾリジン−２−オン誘導体 |
| WO2007081569A2 (en) | 2005-12-30 | 2007-07-19 | Merck & Co., Inc. | Cetp inhibitors |
| US7781426B2 (en) | 2005-12-30 | 2010-08-24 | Merck Sharp & Dohme Corp. | CETP inhibitors |
-
2005
- 2005-01-31 DO DO2005000123A patent/DOP2005000123A/es unknown
- 2005-06-23 MY MYPI20052868A patent/MY167430A/en unknown
- 2005-06-26 JO JOP/2005/0091A patent/JO2994B1/ar active
- 2005-06-28 GT GT200500175A patent/GT200500175A/es unknown
- 2005-06-30 PA PA20058638101A patent/PA8638101A1/es unknown
- 2005-06-30 PE PE2005000763A patent/PE20060525A1/es active IP Right Grant
- 2005-06-30 TW TW094122197A patent/TWI299991B/zh not_active IP Right Cessation
- 2005-07-01 JP JP2007519533A patent/JP4695139B2/ja not_active Expired - Fee Related
- 2005-07-01 RS RS20120497A patent/RS52563B/sr unknown
- 2005-07-01 EP EP11184420A patent/EP2415759A1/en not_active Withdrawn
- 2005-07-01 SI SI200531643T patent/SI1765793T1/sl unknown
- 2005-07-01 NZ NZ552061A patent/NZ552061A/en not_active IP Right Cessation
- 2005-07-01 BR BRPI0512910-9A patent/BRPI0512910A/pt not_active Application Discontinuation
- 2005-07-01 AR ARP050102755A patent/AR049956A1/es not_active Application Discontinuation
- 2005-07-01 DK DK05771445.3T patent/DK1765793T3/da active
- 2005-07-01 CN CN201110245073.3A patent/CN102304096B/zh not_active Expired - Fee Related
- 2005-07-01 US US11/173,295 patent/US7652049B2/en active Active
- 2005-07-01 WO PCT/US2005/023546 patent/WO2006014357A1/en not_active Ceased
- 2005-07-01 GE GEAP20059837A patent/GEP20094694B/en unknown
- 2005-07-01 EA EA200700259A patent/EA011130B1/ru not_active IP Right Cessation
- 2005-07-01 WO PCT/US2005/023775 patent/WO2006014413A1/en not_active Ceased
- 2005-07-01 MX MX2007000035A patent/MX2007000035A/es active IP Right Grant
- 2005-07-01 ES ES05771445T patent/ES2393721T3/es not_active Expired - Lifetime
- 2005-07-01 EP EP05771445A patent/EP1765793B1/en not_active Expired - Lifetime
- 2005-07-01 SV SV2005002160A patent/SV2007002160A/es unknown
- 2005-07-01 CN CN201410720703.1A patent/CN104447603A/zh active Pending
- 2005-07-01 HR HRP20120993TT patent/HRP20120993T1/hr unknown
- 2005-07-01 PL PL05771445T patent/PL1765793T3/pl unknown
- 2005-07-01 CN CN201110245074.8A patent/CN102311401B/zh not_active Expired - Fee Related
- 2005-07-01 PT PT57714453T patent/PT1765793E/pt unknown
- 2005-07-01 AU AU2005270058A patent/AU2005270058B2/en not_active Ceased
- 2005-07-01 CN CN201410720701.2A patent/CN104557757A/zh active Pending
- 2005-07-01 CA CA2570717A patent/CA2570717C/en not_active Expired - Fee Related
- 2005-07-01 US US11/631,821 patent/US20080119476A1/en not_active Abandoned
- 2005-07-01 KR KR1020077000039A patent/KR101204336B1/ko not_active Expired - Fee Related
-
2006
- 2006-12-13 CR CR8808A patent/CR8808A/es unknown
- 2006-12-22 NI NI200600322A patent/NI200600322A/es unknown
- 2006-12-28 IL IL180432A patent/IL180432A/en not_active IP Right Cessation
- 2006-12-28 EC EC2006007124A patent/ECSP067124A/es unknown
-
2007
- 2007-01-03 EG EGNA2007000001 patent/EG27138A/xx active
- 2007-02-01 MA MA29647A patent/MA28780B1/fr unknown
- 2007-02-01 NO NO20070607A patent/NO339808B1/no not_active IP Right Cessation
-
2009
- 2009-11-25 US US12/625,783 patent/US8735435B2/en active Active
-
2010
- 2010-02-16 JP JP2010031195A patent/JP4491062B1/ja not_active Expired - Fee Related
-
2011
- 2011-01-27 JP JP2011015653A patent/JP5543932B2/ja not_active Expired - Fee Related
-
2012
- 2012-01-12 IL IL217530A patent/IL217530A0/en unknown
- 2012-07-30 AR ARP120102770A patent/AR087382A2/es unknown
- 2012-12-21 CY CY20121101259T patent/CY1117930T1/el unknown
-
2014
- 2014-04-14 US US14/252,256 patent/US20140221383A1/en not_active Abandoned
-
2015
- 2015-10-05 US US14/875,438 patent/US20160075724A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013544805A5 (enExample) | ||
| JP2011137006A5 (enExample) | ||
| RU2008131294A (ru) | Ингибиторы сетр | |
| JP2007532651A5 (enExample) | ||
| JP2009522292A5 (enExample) | ||
| JP2015504067A5 (enExample) | ||
| RU2008106243A (ru) | Производные спирохроманона в качестве ингибиторов ацетил коэнзим а карбоксилазы (асс) | |
| CA2570717A1 (en) | Cetp inhibitors | |
| JP2015501833A5 (enExample) | ||
| CO5251463A1 (es) | Compuestos heterociclicos y composicion farmaceutica que coniene dichos compuestos | |
| JP2009534404A5 (enExample) | ||
| HRP20180212T1 (hr) | Derivati 1-fenil-2-piridinilalkil-alkohola kao inhibitori fosfodiesteraze | |
| KR920014805A (ko) | 퀴나졸리논 화합물, 그의 제약학적 조성물 및 그의 제조방법 | |
| ME02675B (me) | Novi derivati cikloheksilamina sa aktivnostima beta2 adrenergijskog agonista i m3 muscarinskog antagonista | |
| JP2008525417A5 (enExample) | ||
| EA200602058A1 (ru) | Производные адамантилпирролидин-2-она в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
| JP2012500260A5 (enExample) | ||
| JP2017538722A5 (enExample) | ||
| YU47588B (sh) | 3-supstituisani-2-oksindol derivati i postupak za njihovo dobijanje | |
| KR950003295A (ko) | 트리시클릭 디아제핀 바조프레신 길항질 및 옥시토신 길항질, 및 이의 제조 방법 | |
| WO2003106428A8 (fr) | Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine | |
| JP2010504286A5 (enExample) | ||
| HRP20080064T5 (en) | Prodrugs of piperazine and substituted piperidine antiviral agents | |
| TW200643015A (en) | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives | |
| HRP20170500T1 (hr) | Heterociklički modulatori sinteze lipida |